Starting July 1, 2026, CMS is opening a temporary program that lets eligible Medicare members get certain GLP-1 weight-loss drugs for a flat $50 a month. Here's how the Bridge works — and the fine print most coverage articles skip.
Whether Medicare covers a GLP-1 isn't a simple yes/no — it depends on what the drug is prescribed to treat. There are three paths:
The fork most articles get wrong: the medical-indication path and the Bridge are mutually exclusive. If you qualify on a medical indication, you use regular Part D; the Bridge is specifically for weight-loss use. Your prescriber decides the indication — not you, and not an agent. (Sources: CMS.gov; SSA §1860D-2(e)(2); FDA. Verify your exact plan.)
The Medicare GLP-1 Bridge is a nationwide CMS demonstration that runs July 1, 2026 through December 31, 2027. It gives eligible Medicare Part D beneficiaries access to certain GLP-1 medications for weight reduction and maintenance — currently Wegovy (all forms), Zepbound KwikPen (the pen only, not single-dose vials), and Foundayo. The headline feature is a flat $50 monthly copay that does not go up as your dose increases. (Source: CMS.gov, Medicare GLP-1 Bridge.)
Eligibility is based on your BMI at the time therapy starts (not today's number), through one of three pathways:
Your Medicare drug plan also has to participate (PDP, MA-PD, SNP, and EGWP plans can; PFFS, PACE, and cost plans are excluded). These exact thresholds are set by CMS — confirm the current eligibility rules at CMS.gov and check that your specific plan participates.
The Bridge sits outside the normal Part D benefit, which changes the math: your Part D deductible doesn't apply, the $50 copay does not count toward your TrOOP (true out-of-pocket / catastrophic threshold) or the 2026 $2,100 cap, and there is no low-income subsidy (LIS) on this $50 — even dual-eligible members pay the full $50. Manufacturer copay coupons can't be applied either.
How you actually get it (there's no sign-up): you don't enroll in the Bridge. Your prescriber submits a prior authorization and prescription to a single central processor (Humana) — not to your own drug plan. The pharmacy routes the claim automatically. So the action item is a conversation with your doctor, not a form you fill out.
Plan ahead: the Bridge ends December 31, 2027. There is no confirmed successor — the broader BALANCE Model is not launching in Medicare, and the Part D weight-loss exclusion stays on the books. Don't count on this $50 price continuing into 2028. If you start on the Bridge, ask your prescriber and plan early about what your options would be after it sunsets. (Source: CMS.gov.)
If you're on a Medicare drug plan and your doctor has discussed a GLP-1, this is worth raising before July. Start with the question at the top: what would it be prescribed for? That tells you whether you're looking at regular Part D or the Bridge. Eligibility and covered uses are set by CMS — confirm the current details at CMS.gov and with your prescriber, and use Medicare's Plan Finder to see how your plan lists the drug. If you're weighing plans during AEP (Oct 15–Dec 7), a licensed agent can help you compare drug coverage against your full needs. Use the enrollment finder to check your window.
These free tools handle one client at a time. Our Excel + Google Sheets toolkits run your whole book — client CRM, 60-day renewal radar, IRMAA appeals, commission & chargeback tracking, and compliance logs. Built for agents, instant download, no monthly fee.
New here? Start for $7.49 →Don't buy the whole system on faith. Grab the Medicare AEP Tracker — your daily command center for enrollment season — for $7.49, instant download. See exactly how our Excel + Google Sheets tools work, then scale up to the full agent CRM when you're ready.
Get the $7.49 AEP Tracker →The dates, penalties, IRMAA brackets, and compliance rules agents reference all season — one page, 2026-current. Get it free, plus occasional tools that save you time.
Under the Medicare GLP-1 Bridge (July 1, 2026–Dec 31, 2027), eligible Part D members pay a flat $50 per month for covered GLP-1 drugs used for weight loss, and that copay does not rise as the dose increases. If a GLP-1 is covered under regular Part D for a medical condition instead, the cost follows your plan's normal tier and counts toward the 2026 $2,100 out-of-pocket cap.
A GLP-1 prescribed for an FDA-approved medical condition can be covered under regular Part D — for example Type 2 diabetes (Ozempic, Mounjaro, Rybelsus), Wegovy for cardiovascular risk reduction, or Zepbound for obstructive sleep apnea. Coverage is not guaranteed: it depends on your plan's formulary, tier, prior authorization, and step therapy. Check your plan and confirm the prescribed use with your doctor.
As of its launch the Bridge covers Wegovy (all forms), Zepbound KwikPen, and Foundayo when used for weight reduction and maintenance. Confirm the current list at CMS.gov.
Eligibility is based on your BMI when therapy starts, through one of three pathways: BMI 35+ (no other condition needed); BMI 30+ with heart failure, uncontrolled hypertension, or CKD stage 3a+; or BMI 27+ with pre-diabetes, prior heart attack, prior stroke, or peripheral artery disease. Your drug plan must also participate. Confirm the exact current rules at CMS.gov.
There is no beneficiary sign-up. Your prescriber submits a prior authorization and prescription to a central processor (Humana), and the pharmacy routes the claim automatically. The step you take is talking to your doctor — no Bridge enrollment form exists.
No. The Bridge is outside the Part D benefit, so the $50 copay does not count toward your TrOOP/catastrophic threshold or the $2,100 cap, the Part D deductible does not apply, and no low-income subsidy reduces it — even dual-eligible members pay the full $50.
The Bridge ends December 31, 2027, and there is no confirmed successor program — the Part D weight-loss exclusion remains in law. Don't assume the $50 price continues into 2028; ask your prescriber and plan about options before it sunsets.
Figures on this page are verified against U.S. government primary sources: